ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.110

-6.8%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bgscolt	11/14/2025 8:12:44 PM
	1 Recommendation Recommended By bobbseytwins2001 Read Replies (1) of 1254

Are there any thoughts on what we can expect from the Saudi investment summit in DC next week. Patrick is speaking on the 19th in the health care portion, are we expecting an investment from the Saudi's from the May MOU, if so what kind of investments are likely. Chat gpt answers: Likely forms of investment Clinical trial funding: Saudi research centers (KFSHRC, KAIMRC) are expected to co-finance trials to expand ANKTIVA’s indications beyond bladder cancer. Infrastructure build-out: Investment in biomanufacturing facilities and digital health monitoring systems to support Cancer Bio Shield deployment. Equity or joint ventures: While not confirmed, Saudi sovereign wealth funds (like PIF) may take equity stakes or joint venture positions to accelerate biotech localization. Market expansion: Support for regulatory pathways and distribution in the Middle East, opening new revenue streams for IBRX. In short: expect Saudi-backed clinical trials, infrastructure investment, and possible equity participation in Immunity Bio, with details likely unveiled at the Washington summit

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next